Please see below a message from Colin Cable. Please email your comments directly to Colin and cc to me so that I can collate them for the Group.
MDS standards for consultation
For over 20 years, monitored dosage systems and compliance aids have been used in the UK in the delivery of medicines to patients. While monitored dosage system packaging has been used primarily in care home or nursing home settings, compliance aids are mainly used by individual patients in the home environment. Both monitored dosage systems and compliance aids require medicines to be removed from the manufacturer's original packaging and repackaged into these alternative packaging systems.
When considering the best way to dispense medicines for a patient, the circumstances of the individual patient must always be taken into account. While monitored dosage systems and compliance aids are undoubtedly appropriate for some patients, they will not be suitable for all patients.
To address some of the issues surrounding the selection and use of these types of packaging, the Royal Pharmaceutical Society has drawn up draft Professional Standards for the use of monitored dosage systems and compliance aids. This is the first set of Professional Standards the Royal Pharmaceutical Society has prepared and they aim to set out what is good practice.
The Professional Standards address many issues including how suitable patients should be selected; assessing the evidence around the use of monitored dosage systems and compliance aids; how to determine if a medicine is suitable for transfer from the manufacturer's original packaging; what is a suitable expiry date for any transferred medicines; and liability issues for pharmacists. The ultimate aim of the Professional Standards is to ensure patients receive a high and individualised level of pharmaceutical service, and that the quality of any medicines administered is assured.
A copy of the draft Royal Pharmaceutical Society Professional Standards for the Use of Monitored Dosage Systems and Compliance Aids is attached (see the link at the top) Any comments that the National Clinical Trials Group wish to submit should be sent to Dr Colin Cable, Pharmaceutical Science Information Advisor, Royal Pharmaceutical Society (email@example.com ; direct telephone 0131 524 2009) by Friday 28th October 2011.
The Royal Pharmaceutical Society is grateful for all contributions. All contributors will be acknowledged and a list of authors will accompany any published material. The Royal Pharmaceutical Society will seek to base the final content on the view best supported by the available evidence and which is likely to have the best impact on improving patient care.
||PhD, MRPharmS - Pharmaceutical Science Information Advisor
Direct:0131 524 2009 Fax:0131 558 8850
|Holyrood Park House, 106 Holyrood Road, Edinburgh, EH8 8AS